East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Betamethasone Dipropionate Cream USP, 0.05%. Aurobindo Pharma’s Betamethasone Dipropionate Cream USP, are an AB-rated generic equivalent to the reference listed drug (RLD), Betamethasone Dipropionate Cream USP, manufactured by Fougera Pharmaceuticals Inc.

Betamethasone Dipropionate Cream USP, are indicated for the:

• Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses